Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Maike N. Nickelsen

Hamburg, HH, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Hamburg, HH, DE 
OverviewLocationsClinical Research

Overview

Maike Nickelsen practices in Hamburg, Germany. Ms. Nickelsen is rated as an Advanced expert by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Primary Mediastinal B-Cell Lymphoma (PMBCL).

Gender
Female

Locations

Hamburg, HH, Germany
Other Locations
Asklepios Hospital St. Georg, Lohmuehlenstrasse 5, St. Georg, HH 20099, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Enrollment Status: Recruiting
Publish Date: December 19, 2017
Intervention Type: Drug
Study Drugs: R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT Conditioning, Ibrutinib (Maintenance)
Study Phase: Phase 3

20 Total Publications

Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6).
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6).
Journal: Annals of hematology
Published: October 26, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Nickelsen's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile